Generic Ceftin ( Cefuroxime )

Buy Generic Ceftin (Cefuroxime) without prescription in Canada

In our Canadian pharmacy, you can buy Ceftin (Cefuroxime) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Ceftin (cefuroxime axetil) is a second‑generation cephalosporin antibiotic used to treat a wide variety of bacterial infections, including those of the respiratory tract, middle ear, sinuses, skin, urinary tract, and early Lyme disease. It works by binding to penicillin‑binding proteins (PBPs) and inhibiting cell wall synthesis in susceptible bacteria, leading to cell lysis and death. Cefuroxime axetil is an oral prodrug that is rapidly hydrolysed to the active cefuroxime after absorption, and its spectrum includes many Gram‑positive and Gram‑negative organisms, including certain beta‑lactamase‑producing strains.

Usual adult dose: For most mild to moderate infections, the recommended dose is 250 mg taken orally every 12 hours. For more severe infections or those caused by less susceptible organisms (e.g., lower respiratory tract infections), the dose may be increased to 500 mg every 12 hours. For uncomplicated urinary tract infections, 250 mg every 12 hours is usually sufficient. For early Lyme disease, 500 mg twice daily for 20 days is recommended. Tablets should be taken with food to enhance absorption and reduce gastrointestinal upset. The tablet may be crushed or split if necessary, but it has a bitter taste that can be masked by mixing with food.

Dosage form: Film‑coated oral tablets containing 250 mg or 500 mg of cefuroxime (as cefuroxime axetil). An oral suspension is also available for paediatric patients and those who cannot swallow tablets.

Onset of action: Cefuroxime axetil is rapidly absorbed after oral administration with food, reaching peak plasma concentrations within 2 to 3 hours. Clinical improvement, such as fever reduction and symptom relief, is typically seen within 48 to 72 hours of starting therapy, though the full course must be completed to ensure bacterial eradication.

Duration of action: The elimination half‑life of cefuroxime is approximately 1 to 2 hours in patients with normal renal function. The antibiotic effect is maintained with twice‑daily dosing. Therapeutic concentrations in tissues and urine exceed the minimum inhibitory concentration (MIC) for susceptible pathogens throughout the dosing interval.

Alcohol recommendation: Alcohol consumption does not directly interfere with the antibacterial action of Ceftin. However, alcohol should be limited during treatment because it can worsen gastrointestinal side effects such as nausea and diarrhoea, impair the immune response, and contribute to dehydration. There is no disulfiram‑like reaction.

Most common side effects: Diarrhoea, nausea, vomiting, abdominal pain, and headache. Skin rash and urticaria may occur, particularly in patients with a history of penicillin allergy, as cross‑sensitivity between cephalosporins and penicillins is possible. Other serious but rare adverse effects include pseudomembranous colitis (Clostridioides difficile‑associated diarrhoea), anaphylaxis, severe cutaneous adverse reactions, and blood dyscrasias.

Would you like to try Ceftin (Cefuroxime) without a prescription?

General Information about Ceftin (Cefuroxime)

• INN (International Nonproprietary Name): Cefuroxime (as cefuroxime axetil).
• Brand names available in Canada: Ceftin® (GlaxoSmithKline Inc.) is the original brand‑name product. Generic versions are widely available and include APO‑Cefuroxime (Apotex Inc.), TEVA‑Cefuroxime (Teva Canada Limited), Sandoz Cefuroxime (Sandoz Canada Inc.), PMS‑Cefuroxime (Pharmascience Inc.), and others. Cefuroxime is also available in an injectable form (cefuroxime sodium) under the brand name Zinacef®.
• ATC code: J01DC02 (cefuroxime; second‑generation cephalosporins).
• Dosage forms and strengths: Film‑coated oral tablets: 250 mg and 500 mg of cefuroxime (as cefuroxime axetil). Powder for oral suspension: 125 mg/5 mL and 250 mg/5 mL after reconstitution.
• Manufacturers in Canada: GlaxoSmithKline Inc. (Ceftin), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Ceftin has been available in Canada since the late 1980s. DINs: 00794182 (Ceftin 250 mg), 00794190 (Ceftin 500 mg), and numerous generic DINs. Multiple formulations are currently marketed and available by prescription.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Cefuroxime axetil is an oral prodrug that, after absorption, is rapidly hydrolysed by esterases in the intestinal mucosa and blood to free cefuroxime. Cefuroxime is a bactericidal second‑generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs), the transpeptidase enzymes responsible for cross‑linking peptidoglycan chains. Inhibition of these enzymes results in a weakened cell wall, osmotic instability, and cell lysis. Cefuroxime is stable against many beta‑lactamases produced by Gram‑positive and Gram‑negative bacteria, extending its spectrum to include common respiratory pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and methicillin‑susceptible Staphylococcus aureus (MSSA). It is also active against many Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. It is not active against Pseudomonas aeruginosa, Enterococcus, or Bacteroides fragilis.

Following oral administration, the axetil prodrug is best absorbed when taken with food; the absolute bioavailability of cefuroxime increases from approximately 37% (fasting) to 52% (with food). Peak serum concentrations of cefuroxime are attained 2 to 3 hours after dosing. The drug is widely distributed into body tissues and fluids, including the middle ear, bronchial secretions, and urine. Approximately 50% of cefuroxime is bound to plasma proteins. Cefuroxime is not significantly metabolised and is excreted almost entirely unchanged by the kidneys, primarily through glomerular filtration and tubular secretion. The elimination half‑life is 1 to 2 hours in adults with normal renal function; this is prolonged in neonates, the elderly, and patients with renal impairment. Dose adjustment is required for patients with creatinine clearance below 30 mL/min. Cefuroxime is moderately removed by haemodialysis.

Indications

• Upper respiratory tract infections: Pharyngitis/tonsillitis caused by Streptococcus pyogenes, acute otitis media, and acute bacterial sinusitis.
• Lower respiratory tract infections: Acute exacerbations of chronic bronchitis and community‑acquired pneumonia caused by susceptible organisms.
• Skin and soft tissue infections: Uncomplicated cellulitis and impetigo caused by MSSA and Streptococcus pyogenes.
• Urinary tract infections: Uncomplicated and complicated UTIs, including cystitis and pyelonephritis, caused by susceptible Gram‑negative organisms.
• Early Lyme disease (erythema migrans): Cefuroxime axetil 500 mg twice daily for 20 days is an effective alternative to doxycycline for the treatment of early localised or early disseminated Lyme borreliosis in patients who cannot take tetracyclines.
• Gonorrhoea: Cefuroxime axetil is not a first‑line agent for uncomplicated gonococcal infections, but may be used in selected cases.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Cefuroxime axetil is considered safe for use during pregnancy and is classified as a Pregnancy Category B drug. Animal studies have not demonstrated teratogenic effects, and there is extensive clinical experience with cephalosporins in pregnancy. It should be used only when clearly needed and under medical supervision.
• Breastfeeding: Cefuroxime is excreted in human breast milk in low concentrations. Although generally considered compatible with breastfeeding, diarrhoea, candidiasis, or allergic sensitization may occur in the nursing infant. A decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics: Cefuroxime axetil is widely used in children aged 3 months and older. Dosing is weight‑based (typically 15 mg/kg twice daily for most infections; 30 mg/kg twice daily for otitis media). The oral suspension is used for younger children. Safety and efficacy are well established in paediatric populations.
• Elderly: No specific dose adjustment is required for age alone. However, elderly patients are more likely to have age‑related renal impairment, and dosage should be adjusted if creatinine clearance is below 30 mL/min. Monitor for gastrointestinal side effects, including C. difficile colitis.
• Renal impairment: Cefuroxime is primarily excreted by the kidneys. In patients with creatinine clearance below 30 mL/min, the dosing interval should be extended to every 24 hours for the 250 mg dose, or every 12‑24 hours for the 500 mg dose, depending on the degree of impairment. Patients on haemodialysis should receive a supplemental dose after each dialysis session.
• Allergy and hypersensitivity: Cephalosporins can cause allergic reactions, ranging from mild rash to life‑threatening anaphylaxis. Approximately 5‑10% of patients with a history of penicillin allergy may be cross‑allergic to cephalosporins; the risk is higher with immediate‑type (IgE‑mediated) penicillin reactions. If a hypersensitivity reaction occurs, the drug must be discontinued immediately and appropriate emergency treatment instituted. Ceftin should not be administered to patients with a history of severe, immediate hypersensitivity to penicillins or other cephalosporins.
• Clostridioides difficile‑associated diarrhoea (CDAD): As with many antibiotics, Ceftin can cause overgrowth of C. difficile and lead to pseudomembranous colitis, which can range from mild diarrhoea to fatal colitis. CDAD must be considered in any patient who develops diarrhoea during or up to 2 months after antibiotic therapy. Anti‑motility agents should be avoided if CDAD is suspected.
• Drug‑resistant bacteria: To reduce the development of antibiotic resistance, Ceftin should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria. Culture and sensitivity information should guide therapy when available.
• Phenylketonuria (PKU): The oral suspension contains phenylalanine (aspartame), which can be harmful to patients with phenylketonuria. The tablet formulation does not contain aspartame.

Driving and alcohol

Ceftin is not known to impair the ability to drive or operate machinery. Some patients may experience dizziness, headache, or fatigue as part of their underlying infection. Alcohol consumption does not have a direct pharmacokinetic interaction with Ceftin, but it should be limited during treatment because it can exacerbate gastrointestinal side effects and impair the body’s immune response. Alcohol does not cause a disulfiram‑like reaction with this cephalosporin.

Dosage Instructions

• Adults and adolescents (≥ 13 years) — mild to moderate infections: 250 mg taken orally every 12 hours for 7‑10 days, depending on the site and severity of infection. For uncomplicated urinary tract infections, 250 mg every 12 hours for 7‑10 days.
• Severe or complicated infections: 500 mg every 12 hours. For community‑acquired pneumonia or acute exacerbations of chronic bronchitis where less susceptible organisms are suspected, 500 mg twice daily is recommended.
• Early Lyme disease: 500 mg twice daily for 20 days.
• Paediatric dosing (3 months to 12 years): The dose is based on body weight. For most infections: 15 mg/kg twice daily (up to a maximum of 250 mg per dose). For acute otitis media: 30 mg/kg twice daily (up to a maximum of 500 mg per dose if ≥ 2 years). The oral suspension is preferred for children who cannot swallow tablets.
• Renal impairment: For patients with creatinine clearance (CrCl) below 30 mL/min, the dosing interval should be adjusted:
  • CrCl 10‑29 mL/min: 250 mg every 24 hours (or 500 mg every 12‑24 hours for severe infections).
  • CrCl < 10 mL/min (not on dialysis): 250 mg every 48 hours.
  • Haemodialysis patients: Administer a supplemental dose after each dialysis session; the standard twice‑daily schedule may be resumed between dialysis days if clinically appropriate.
• Administration: Ceftin tablets should be taken with food (a meal or a snack) to improve absorption and reduce stomach upset. The tablets should be swallowed whole with a full glass of water. The tablet may be crushed and mixed with food (e.g., applesauce, yogurt) for patients who have difficulty swallowing; however, the crushed tablet has a bitter taste. Do not chew the tablet. The oral suspension must be shaken vigorously before each use and measured with the calibrated dosing device provided by the pharmacy. Complete the entire prescribed course of therapy, even if symptoms improve.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day with food. If it is close to the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose.

Side Effects and Contraindications

• Common side effects (incidence 1‑10%): Diarrhoea (3‑4%), nausea, vomiting, abdominal pain, headache, and skin rash (including urticaria). These are generally mild and self‑limiting.
• Uncommon but serious side effects: Clostridioides difficile‑associated diarrhoea (CDAD; may be severe or fatal), anaphylaxis (rare), Stevens‑Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, acute interstitial nephritis, and blood dyscrasias (eosinophilia, thrombocytopenia, leucopenia). Elevations in liver enzymes (ALT/AST) have been reported.
• Contraindications: Known hypersensitivity to cefuroxime, other cephalosporin antibiotics, or any excipient in the formulation. A history of severe, immediate‑type hypersensitivity reaction (e.g., anaphylaxis) to penicillins or other beta‑lactam antibiotics is a contraindication.

Drug Interactions

• Probenecid: Probenecid competitively inhibits the renal tubular secretion of cefuroxime, resulting in higher and prolonged serum concentrations. This interaction can be used therapeutically but requires careful monitoring if both drugs are co‑administered.
• Oral contraceptives: Cephalosporins, like other broad‑spectrum antibiotics, may transiently reduce the efficacy of combined oral contraceptives by interfering with the enterohepatic circulation of ethinyl estradiol. A backup barrier method of contraception is recommended during treatment and for at least 7 days after completing the antibiotic course.
• Warfarin: Cephalosporins may enhance the anticoagulant effect of warfarin by reducing vitamin K production by gut flora. The International Normalised Ratio (INR) should be monitored more frequently during and after Ceftin therapy, and the warfarin dose adjusted as needed.
• Antacids and H2‑receptor antagonists: Drugs that reduce gastric acidity (e.g., ranitidine, famotidine, sodium bicarbonate) may decrease the absorption of cefuroxime axetil. Ceftin should be taken at least 2 hours before or 2 hours after antacids or H2‑blockers. Proton pump inhibitors (e.g., omeprazole) have a similar but less pronounced effect.
• Loop diuretics (e.g., furosemide) and aminoglycosides: Concomitant use may increase the risk of nephrotoxicity. Renal function should be monitored in patients receiving these combinations.

Practical Advice

• Administration: Take Ceftin with food—a meal or a substantial snack—to enhance absorption and reduce stomach upset. Swallow the tablet whole with a full glass of water. If you cannot swallow the tablet, you may crush it and mix it with a small amount of soft food (e.g., applesauce, yogurt) and swallow the mixture immediately without chewing. The taste will be bitter. For the oral suspension, shake the bottle well before each use and measure the dose with the provided device. Space your doses evenly, ideally every 12 hours (e.g., 8:00 a.m. and 8:00 p.m.). Complete the full prescribed course, even if you feel better.
• Monitoring: No routine laboratory monitoring is required for healthy individuals on short‑term therapy. In patients with renal impairment, monitor renal function before and during treatment; adjust the dosing interval accordingly. For patients on warfarin, monitor INR more frequently. If diarrhoea develops, especially if watery or bloody, contact your doctor before taking any anti‑diarrhoeal medication, as this could be a sign of C. difficile colitis.
• Storage: Store tablets at room temperature (15‑30 °C) in a tightly closed container, protected from moisture and light. The oral suspension should be refrigerated (2‑8 °C) after reconstitution and used within 10 days; discard any unused portion after this time. Do not freeze. Keep all forms out of the reach and sight of children.
• Lifestyle: Drink plenty of fluids while taking this antibiotic to stay hydrated, especially if you develop diarrhoea. Avoid alcohol, which can worsen gastrointestinal side effects and delay recovery. Inform any healthcare professional that you are taking Ceftin, particularly if you are scheduled for surgery, dental work, or laboratory tests. If you have a history of penicillin allergy, notify your doctor; cross‑reactivity is possible.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day with food. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Never double the dose.
• When to seek medical review: Contact your doctor immediately if you develop signs of an allergic reaction (rash, hives, itching, swelling of the face, lips, or tongue, difficulty breathing), severe or watery/bloody diarrhoea, signs of liver problems (yellowing of the skin or eyes, dark urine, right upper abdominal pain), or any new or worsening symptoms. Seek emergency care for anaphylaxis (difficulty breathing, severe swelling, loss of consciousness).
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Amoxicillin (Amoxil®): A penicillin antibiotic that is first‑line for streptococcal pharyngitis and some respiratory infections. It is not beta‑lactamase stable and may be ineffective against resistant organisms.
• Amoxicillin‑clavulanate (Clavulin®, Augmentin®): Combines amoxicillin with a beta‑lactamase inhibitor, extending coverage to include beta‑lactamase‑producing strains of Haemophilus influenzae and Moraxella catarrhalis. It is an alternative for resistant respiratory infections.
• Clarithromycin (Biaxin®) or Azithromycin (Zithromax®): Macrolide antibiotics used for respiratory infections and for patients with penicillin allergy. They are active against atypical organisms and are an alternative when cephalosporins cannot be used. Macrolide resistance among pneumococci is a concern.
• Doxycycline (Vibramycin®): A tetracycline antibiotic that is the first‑line oral agent for early Lyme disease, and it also covers many respiratory pathogens. It is an alternative for penicillin‑allergic patients, but should not be used in children under 8 years of age or during pregnancy.
• Levofloxacin or Moxifloxacin (respiratory fluoroquinolones): Reserved for more severe infections or when first‑line agents have failed. They have broad‑spectrum activity but carry risks of tendinitis, tendon rupture, peripheral neuropathy, and QT prolongation.
• Non‑pharmacological measures: Rest, adequate hydration, and symptomatic management with analgesics/antipyretics (e.g., acetaminophen, ibuprofen) are important supportive measures for bacterial infections.

Clinical Efficacy

Cefuroxime axetil has been extensively studied and has demonstrated high clinical and bacteriological cure rates for a broad range of community‑acquired infections. In acute otitis media, a 10‑day course of cefuroxime axetil (30 mg/kg/day divided twice daily) is effective in approximately 80‑90% of paediatric cases, including those caused by beta‑lactamase‑producing Haemophilus influenzae and Moraxella catarrhalis. For streptococcal pharyngitis, cefuroxime axetil 250 mg twice daily for 10 days achieves bacterial eradication rates exceeding 90%. In lower respiratory tract infections, including acute exacerbations of chronic bronchitis, cefuroxime axetil 250‑500 mg twice daily produces clinical success rates comparable to amoxicillin‑clavulanate and macrolides. For early Lyme disease (erythema migrans), cefuroxime axetil 500 mg twice daily for 20 days is as effective as doxycycline, with resolution of the rash and prevention of late sequelae in over 90% of patients. Cefuroxime is also a recommended alternative in Canadian guidelines for the treatment of community‑acquired pneumonia and acute bacterial sinusitis. Its stability against many common beta‑lactamases, favourable safety profile, and twice‑daily dosing make it a valuable option, particularly when broader‑spectrum coverage is needed. Resistance rates among key respiratory pathogens remain relatively low in Canada, though local susceptibility patterns should always guide empiric therapy.

Important:

Ceftin (cefuroxime axetil) is a prescription cephalosporin antibiotic that should be used only under the supervision of a qualified healthcare professional. It is intended to treat bacterial infections only and is not effective against viral infections such as the common cold or flu. Take the full prescribed course of this medication, even if your symptoms improve earlier. Allergic reactions can occur and may be severe, particularly in patients with a history of penicillin or cephalosporin allergy. Seek immediate medical attention if you develop signs of an allergic reaction such as rash, hives, itching, swelling of the face, lips, or tongue, or difficulty breathing. Diarrhoea is a common side effect, but if it becomes severe, watery, or bloody, contact your doctor immediately, as this may be a sign of a serious intestinal infection (C. difficile colitis). This medication should be taken with food to improve absorption and reduce stomach upset. If you have kidney disease, your dose may need to be adjusted. Inform your doctor if you are pregnant, breastfeeding, or taking any other medications, particularly warfarin, antacids, or oral contraceptives. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Ceftin - Shipping across Canada